White & Case Advises on Intra-Cellular Therapies, Inc.'s US$295 Million Public Offering
1 min read
Global law firm White & Case LLP has advised J.P. Morgan Securities LLC, SVB Leerink LLC and Evercore Group L.L.C., as underwriters, on leading biopharmaceutical company Intra-Cellular Therapies, Inc.'s approximately US$295 million public offering.
The offering included 10 million shares of Intra-Cellular Therapies common stock at a public offering price of US$29.50 per share.
Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel Prize–winning research that allows it to understand how therapies affect the inner workings of cells in the body. The company leverages this intra-cellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. The offering follows Intra-Cellular Therapies recent announcement that the US Food and Drug Administration has approved its drug lumateperone for the treatment of schizophrenia in adults.
The White & Case team was led by partner Stuart Bressman (New York), and included partner Anita Varma (Boston) and associates Alok Choksi, Samuel Chan (both New York) and Yang Xu (Silicon Valley).
For more information, please speak to your local media contact.